Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug

George Pettit, Monte R. Rhodes

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Combretastatin A-4 as the phosphate ester prodrug (3d) is a potent antineoplastic and antiangiogenesis substance and is in advanced preclinical development. For the purpose of improving the phosphorylation synthetic sequence from combretastatin A-4, new routes were investigated. The phosphorylation step was found to be considerably improved using in situ-generated dibenzyl chlorophosphite. Cleavage of the benzyl esters employing a trimethylchlorosilane/sodium iodide procedure, followed by treatment with sodium methoxide, led to the water-soluble prodrug (3d) in high yield.

Original languageEnglish (US)
Pages (from-to)183-191
Number of pages9
JournalAnti-Cancer Drug Design
Volume13
Issue number3
StatePublished - Apr 1998

Fingerprint

Phosphorylation
Prodrugs
Antineoplastic Agents
Esters
Sodium Iodide
Methanol
Phosphates
Water
fosbretabulin
trimethylchlorosilane

Keywords

  • Antineoplastic agents
  • Combretastatin A-4 prodrug
  • Phosphate esters

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Oncology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. / Pettit, George; Rhodes, Monte R.

In: Anti-Cancer Drug Design, Vol. 13, No. 3, 04.1998, p. 183-191.

Research output: Contribution to journalArticle

@article{27bee088c3194b4a9cbf04597afc5ce0,
title = "Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug",
abstract = "Combretastatin A-4 as the phosphate ester prodrug (3d) is a potent antineoplastic and antiangiogenesis substance and is in advanced preclinical development. For the purpose of improving the phosphorylation synthetic sequence from combretastatin A-4, new routes were investigated. The phosphorylation step was found to be considerably improved using in situ-generated dibenzyl chlorophosphite. Cleavage of the benzyl esters employing a trimethylchlorosilane/sodium iodide procedure, followed by treatment with sodium methoxide, led to the water-soluble prodrug (3d) in high yield.",
keywords = "Antineoplastic agents, Combretastatin A-4 prodrug, Phosphate esters",
author = "George Pettit and Rhodes, {Monte R.}",
year = "1998",
month = "4",
language = "English (US)",
volume = "13",
pages = "183--191",
journal = "Anti-Cancer Drug Design",
issn = "0266-9536",
publisher = "Cognizant Communication Corporation",
number = "3",

}

TY - JOUR

T1 - Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug

AU - Pettit, George

AU - Rhodes, Monte R.

PY - 1998/4

Y1 - 1998/4

N2 - Combretastatin A-4 as the phosphate ester prodrug (3d) is a potent antineoplastic and antiangiogenesis substance and is in advanced preclinical development. For the purpose of improving the phosphorylation synthetic sequence from combretastatin A-4, new routes were investigated. The phosphorylation step was found to be considerably improved using in situ-generated dibenzyl chlorophosphite. Cleavage of the benzyl esters employing a trimethylchlorosilane/sodium iodide procedure, followed by treatment with sodium methoxide, led to the water-soluble prodrug (3d) in high yield.

AB - Combretastatin A-4 as the phosphate ester prodrug (3d) is a potent antineoplastic and antiangiogenesis substance and is in advanced preclinical development. For the purpose of improving the phosphorylation synthetic sequence from combretastatin A-4, new routes were investigated. The phosphorylation step was found to be considerably improved using in situ-generated dibenzyl chlorophosphite. Cleavage of the benzyl esters employing a trimethylchlorosilane/sodium iodide procedure, followed by treatment with sodium methoxide, led to the water-soluble prodrug (3d) in high yield.

KW - Antineoplastic agents

KW - Combretastatin A-4 prodrug

KW - Phosphate esters

UR - http://www.scopus.com/inward/record.url?scp=0031980124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031980124&partnerID=8YFLogxK

M3 - Article

C2 - 9595032

AN - SCOPUS:0031980124

VL - 13

SP - 183

EP - 191

JO - Anti-Cancer Drug Design

JF - Anti-Cancer Drug Design

SN - 0266-9536

IS - 3

ER -